ImmunityBio Inc Ordinary Shares IBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Trading Information
- Previous Close Price
- $6.75
- Day Range
- $6.51–6.85
- 52-Week Range
- $1.95–12.43
- Bid/Ask
- $6.57 / $6.63
- Shares Outstanding
- 1.06B
- Market Cap
- $7.10B
- Volume/Avg
- 109,224 / 12M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 37.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 691
- Website
- https://www.immunitybio.com
Valuation
Metric | IBRX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 37.70 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IBRX |
|---|---|
Quick Ratio | 3.96 |
Current Ratio | 4.27 |
Interest Coverage | −8.39 |
Quick Ratio
IBRX
Profitability
Metric | IBRX |
|---|---|
Return on Assets (Normalized) | −128.43% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
IBRX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|dlPWrd$ | LOCK|Y><$K | $139B | |||
| Moderna Inc MRNA | LOCK|gV?zmW | LOCK|#J | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|@c#F#>? | LOCK|&NvC | $99B | |||
| argenx SE ADR ARGX | LOCK|nx!?k% | LOCK|FC | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|hrpLSh | LOCK|S&Y | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^&qcJ>q< | LOCK|VJb# | $31B | |||
| Incyte Corp INCY | LOCK|#%>xtpY | LOCK|!& | $25B | |||
| BioNTech SE ADR BNTX | LOCK|s^&%$wV | LOCK|RT# | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|PyP<b^$ | LOCK|$>F>g | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$c$!<Y# | LOCK|>H | $16B |
United States